Drug profile

The FDA adverse-event record for Mupirocin

111 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mupirocin. See the species affected, top reactions, and outcomes below.

111
adverse-event reports
19.8%
death-coded share
Dog
most-reported species
21
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
111
Total Reports
22
Deaths Reported
19.8%
Death Rate

Active Ingredients

Mupirocin

Administration Routes

TopicalUnknownOralOtherAuricular (Otic)

Species Affected

Dog 80
Cat 29
Other Birds 1
Human 1

Most Affected Breeds

Domestic Shorthair 21
Retriever - Labrador 11
Shepherd Dog - German 10
Terrier - West Highland White 5
Retriever - Golden 4
Shih Tzu 4
Cat (unknown) 3
Dog (other) 3
Terrier - Bull - American Pit 3
Terrier - Bull 3

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 21
Diarrhoea 18
Vomiting 17
Anorexia 15
Other abnormal test result NOS 15
Death by euthanasia 15
Neutrophilia 10
Leucocytosis NOS 10
Lack of efficacy - NOS 10
Behavioural disorder NOS 9
Ataxia 9
Not eating 9

Outcome Breakdown

Ongoing
45 (41.7%)
Outcome Unknown
24 (22.2%)
Recovered/Normal
15 (13.9%)
Euthanized
13 (12.0%)
Died
9 (8.3%)
Recovered with Sequela
2 (1.9%)

Mupirocin Adverse Event Insights

111 reports name Mupirocin; 22 recorded a death outcome (19.8% of reported events, not a population-level mortality rate). Active ingredient: Mupirocin. Administration routes: Topical, Unknown, Oral, Other.

By species: Dog (80 reports), Cat (29 reports), Other Birds (1 reports). By breed: Domestic Shorthair (21), Retriever - Labrador (11), Shepherd Dog - German (10).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (21), Diarrhoea (18), Vomiting (17), Anorexia (15). Outcome, 108 coded reports: Ongoing leads at 41.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.